港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

728.939

-15.659-2.10%

涨家数：14

跌家数：18

平家数：2

市盈率：- -

高：744.967

开：744.496

低：723.794

收：744.598

数据加载中...

第3项！康方生物PD-1/VEGF双抗新适应症申报上市

云顶新耀(01952.HK)宣布配售股份拟集资约15.725亿港元

《盈警》科济药业(02171.HK)料上半年净亏损按年收窄至不逾8,000万人币

阿斯达克财经

医药巨头：要让美国药价“减半”很简单

华尔街见闻

科济药业-B(02171)预期中期净亏损和经调整净亏损同比减少

科济药业-B：盈利预告－预期亏损减少

香港交易所

云顶新耀拟先旧后新配股总筹15.7亿港元加速全球研发及商业化布局

云顶新耀：根据一般授权配售现有股份及以先旧后新方式认购新股份。

云顶新耀(01952.HK)拟先旧后新配售2256.1万股净筹15.53亿港元

Telomir制药公司股价因早衰症治疗结果喜人而飙升

光大证券-医药生物行业国务院新闻办新闻发布会点评：医药集采反内卷推动价值重估，支持创新长逻辑坚挺-250724

收涨100%！这家0收入创新药企要火？

中国基金报

同源康医药-B(02410.HK)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录

同源康医药-B(02410)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录

华昊中天医药-B(02563.HK)委任大信会计师事务所(特殊普通合伙)为核数师

华昊中天医药-B委任大信为公司新核数师

康沣生物-B(06922)：哮喘冷冻消融系统获得美国食品及药物管理局授予的突破性医疗器械认证

智通财经网

大摩：未来医药在创新升级、制造升级及消费升级方面均有较大发展潜力医药长期投资逻辑稳固

中国抗体-B(03681)授出4658.6万份购股权

KT International Investment Limited增持开拓药业-B(09939)50万股每股作价2.598港元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":728.93866,"timestamp":1753430886241,"preClose":744.5975,"halted":0,"volume":295989198,"delay":0,"changeRate":-0.02103,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-15.658813,"latestTime":"07-25 16:00:00","open":744.49634,"high":744.967,"low":723.794,"amount":7101826928,"amplitude":0.028435,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"pbRate":5.862148,"peRate":-36.113023,"turnoverRate":0.011111,"increases":13,"decrements":20,"flats":0,"marketCap":427345468672,"floatMarketCap":392843141040},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":744.967,"amplitude":0.028435,"preClose":744.5975,"low":723.794,"pbRate":"5.862148","latestPrice":728.93866,"volume":295989198,"delay":0,"open":744.49634,"prevYearClose":331.1933,"prevWeekClose":711.682,"prevMonthClose":555.617,"prevQuarterClose":555.617,"fiveDayClose":711.682,"twentyDayClose":566.494,"sixtyDayClose":466.153,"secType":"PLATE","market":"HK","turnoverRate":0.011111,"peRate":-36.113023,"marketCap":427345468672,"floatMarketCap":392843141040,"timestamp":1753430886241,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":14,"down":18,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2554312167","title":"第3项！康方生物PD-1/VEGF双抗新适应症申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2554312167","media":"医药魔方","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554312167?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:41","pubTimestamp":1753404089,"startTime":"0","endTime":"0","summary":"7月25日，国家药品监督管理局药品审评中心官网显示，康方生物的依沃西单抗新适应症上市申请已获受理。依沃西单抗是康方生物自主研发的、全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物。此次申报的适应症为第3项。与治疗相关的严重不良反应发生率以及三级及以上出血事件发生率与对照组相似。HARMONi-6研究是依沃西在非小细胞肺癌领域取得的第3个显著阳性结果的III期临床研究，填补了抗血管生成机制药物在sq-NSCLC中不可用的巨大临床空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725085834971d1d1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725085834971d1d1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0417516571.SGD","BK1161","LU1720050803.USD","BK1574","09926","LU0348783233.USD","LU0348784397.USD","IE00B543WZ88.USD","LU2488822045.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2554373193","title":"云顶新耀(01952.HK)宣布配售股份 拟集资约15.725亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554373193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554373193?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:37","pubTimestamp":1753403868,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01952","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2554731733","title":"《盈警》科济药业(02171.HK)料上半年净亏损按年收窄至不逾8,000万人币","url":"https://stock-news.laohu8.com/highlight/detail?id=2554731733","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554731733?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:17","pubTimestamp":1753402620,"startTime":"0","endTime":"0","summary":"科济药业发盈警，基于CT053的商业化及CT041的新药申请获国家药品监督管理局接纳，预期上半年将出现净亏损和经调整净亏损按年减少，料净亏损不超过约8,000万元人民币(下同)，相对于去年同期亏损3.51亿元；经调整净亏损的净亏损不超过约7,500万元，去年同期为亏损3.42亿元。沽空资料截至 2025-07-24 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20211223145802440_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20211223145802440_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1455904/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1585","BK1574","02171","BK1587","BK1161"],"gpt_icon":0},{"id":"2554731544","title":"医药巨头：要让美国药价“减半”很简单","url":"https://stock-news.laohu8.com/highlight/detail?id=2554731544","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554731544?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:16","pubTimestamp":1753402564,"startTime":"0","endTime":"0","summary":"特朗普签署行政令猛砍药价，让美国人支付其他发达国家支付的药品最低价，这无疑将对制药行业构成重大打击。面对药价改革威胁，制药巨头罗氏提出绕过中间商直销的解决方案，称此举可轻松实现药价减半目标。“如果美国希望将药价削减50%，这非常容易。我们直接销售就行。”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3751853","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3751853","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","BK1515","BK1574","09939","BK1161"],"gpt_icon":0},{"id":"2554627739","title":"科济药业-B(02171)预期中期净亏损和经调整净亏损同比减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2554627739","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554627739?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:09","pubTimestamp":1753402161,"startTime":"0","endTime":"0","summary":"详情介绍如下：与截至2024年6月30日止6个月的约人民币3.51亿元相比，报告期间的净亏损不超过约人民币8000万元;及与截至2024年6月30日止6个月的约人民币3.42亿元相比，报告期间的经调整净亏损(指不包括以股份为基础的薪酬(经调整项目)的净亏损，为一项非国际财务报告准则计量标准不超过约人民币7500万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科济药业-B(02171)预期中期净亏损和经调整净亏损同比减少","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1585","BK1587","02171","BK1161"],"gpt_icon":0},{"id":"2554795075","title":"科济药业-B：盈利预告－预期亏损减少","url":"https://stock-news.laohu8.com/highlight/detail?id=2554795075","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554795075?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 08:00","pubTimestamp":1753401615,"startTime":"0","endTime":"0","summary":"亏损收窄主要归因于三个方面：CT053在中国内地的商业化收益增加、外汇波动带来的影响，以及CT053和CT041的研发支出大幅减少。值得注意的是，CT041的新药申请已获国家药品监督管理局接纳审查。科济药业发布盈利预告，预计2025年上半年净亏损将显著减少至不超过人民币8000万元，相比2024年同期的人民币3.51亿元大幅改善。公司预计将于2025年8月末之前发布详细的中期业绩报告。有用没用该公告为独立文件：","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725233657971eabf4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725233657971eabf4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02171","BK1587","BK1161","BK1574","BK1585"],"gpt_icon":0},{"id":"2554173958","title":"云顶新耀拟先旧后新配股总筹15.7亿港元 加速全球研发及商业化布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2554173958","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554173958?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 07:56","pubTimestamp":1753401360,"startTime":"0","endTime":"0","summary":"待售股份数目相当于本公告日期已发行股份总数约6.87%；及紧随认购事项完成后经配发及发行认购股份扩大的已发行股份总数约6.43%。认购股份将根据一般授权予以发行，公司将向联交所申请批准认购股份上市及买卖。假设全部待售股份获悉数配售及认购股份由卖方认购，则配售事项及认购事项所得款项总额预期约为15.725亿港元，而所得款项净额将约为15.534亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072507572594b93e4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072507572594b93e4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","BK1583","01952"],"gpt_icon":0},{"id":"2554739584","title":"云顶新耀：根据一般授权配售现有股份及以先旧后新方式认购新股份。","url":"https://stock-news.laohu8.com/highlight/detail?id=2554739584","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554739584?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 07:51","pubTimestamp":1753401114,"startTime":"0","endTime":"0","summary":"云顶新耀：根据一般授权配售现有股份及以先旧后新方式认购新股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072507553094b93d81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072507553094b93d81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01952","BK1574","BK1161"],"gpt_icon":0},{"id":"2554739819","title":"云顶新耀(01952.HK)拟先旧后新配售2256.1万股 净筹15.53亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554739819","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554739819?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 07:50","pubTimestamp":1753401041,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","01952","BK1574","BK1583"],"gpt_icon":0},{"id":"2554784259","title":"Telomir制药公司股价因早衰症治疗结果喜人而飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2554784259","media":"英为财情","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554784259?lang=zh_cn&edition=fundamental","pubTime":"2025-07-25 00:18","pubTimestamp":1753373880,"startTime":"0","endTime":"0","summary":"Investing.com --  Telomir Pharmaceuticals  Inc 股价跳涨15%，此前这家临床前阶段生物技术公司宣布了新的研究结果，显示其主要化合物能够恢复亨廷顿-吉尔福德早衰综合症患者细胞的线粒体功能。该公司的化合物Telomir-1展示了在不触发氧化应激或细胞增殖的情况下恢复病变细胞能量的能力。关键发现表明，Telomir-1在基础和应激条件下显著增加了线粒体能量产生，同时减少了活性氧物质。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2901800","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investing_news","symbols":["01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2554803507","title":"光大证券-医药生物行业国务院新闻办新闻发布会点评：医药集采反内卷推动价值重估，支持创新长逻辑坚挺-250724","url":"https://stock-news.laohu8.com/highlight/detail?id=2554803507","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554803507?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 23:38","pubTimestamp":1753371480,"startTime":"0","endTime":"0","summary":"事件：　　2025年7月24日，国家医保局局长章轲等出席国务院新闻办公室新闻发布会介绍“十四五”时期深化医保改革，服务经济社会发展有关情况。“十四五”以来累计402种新药纳入医保目录，2024年创新药医保支出达2020年的3.9倍，年均增速40%，彰显医保基金对临床价值突出的创新成果的快速接纳。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-24/doc-infhrcyi2386602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","163118","06178","BK0012","BK0276","601788","BK1161","BK1574","159938","BK0028","BK1564","BK1147","BK1515","BK0188","09939","000808.SH"],"gpt_icon":0},{"id":"2553145789","title":"收涨100%！这家0收入创新药企要火？","url":"https://stock-news.laohu8.com/highlight/detail?id=2553145789","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553145789?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 22:52","pubTimestamp":1753368748,"startTime":"0","endTime":"0","summary":"在港股创新药的大行情下，目前0收入且亏损的维立志博获得港股市场追捧。利弗莫尔证券暗盘交易显示，截至收盘，将于7月25日（周五）在港股挂牌上市的维立志博以70.05港元报收，较35港元的招股价上涨100.14%；每手100股，不计手续费，每手赚3505港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507243466814271.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507243466814271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2553789679","title":"同源康医药-B(02410.HK)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录","url":"https://stock-news.laohu8.com/highlight/detail?id=2553789679","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553789679?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 22:51","pubTimestamp":1753368686,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02410","BK1574","BK1583","BK1141","BK1161","159938","03347","09939","TY","BK1515","BK1576"],"gpt_icon":0},{"id":"2553678967","title":"同源康医药-B(02410)：TY-302、TY-2699a及TY-0540的I期临床试验结果获2025年欧洲肿瘤内科学会(ESMO)大会以壁报形式收录","url":"https://stock-news.laohu8.com/highlight/detail?id=2553678967","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553678967?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 22:51","pubTimestamp":1753368686,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，公司自主研发的三款临床产品TY-302、 TY-2699a及TY-0540的I期临床试验结果，正式获2025年欧洲肿瘤内科学会 大会以壁报形式收录。初步临床数据显示，TY-2699a在同类剂量水平下兼具优异安全性和初步疗效。TY-0540是一种选择性CDK2抑制剂，拟用于治疗乳腺癌、卵巢癌及前列腺癌等其他实体瘤。欧洲肿瘤内科学会成立于1975年，是全球领先的肿瘤学专业学术组织。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02410","BK1574","BK1515","TY","BK1141","BK1161","03347","159938","BK1576","BK1583","09939"],"gpt_icon":0},{"id":"2553278969","title":"华昊中天医药-B(02563.HK)委任大信会计师事务所(特殊普通合伙)为核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2553278969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553278969?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 22:46","pubTimestamp":1753368404,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","159938","02563","BK1161","09939"],"gpt_icon":0},{"id":"2553789522","title":"华昊中天医药-B委任大信为公司新核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2553789522","media":"格隆汇","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553789522?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 22:39","pubTimestamp":1753367971,"startTime":"0","endTime":"0","summary":"格隆汇7月24日丨华昊中天医药-B(02563.HK)公告，大信国际(香港)会计师事务所退任公司核数师。董事会已议决于大信退任后建议委任大信会计师事务所(特殊普通合伙)为公司核数师。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072422394194b8858b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072422394194b8858b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","02563","BK1515","BK1574"],"gpt_icon":0},{"id":"2553786386","title":"康沣生物-B(06922)：哮喘冷冻消融系统获得美国食品及药物管理局授予的突破性医疗器械认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2553786386","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553786386?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 21:56","pubTimestamp":1753365398,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康沣生物-B 发布公告，于2025年7月24日，集团的哮喘冷冻消融系统，集团的呼吸介入产品之一，由冷冻治疗设备及气道冷冻消融导管组成，已获得美国食品及药物管理局授予的突破性医疗器械认证。哮喘冷冻消融系统为用于治疗中度及重度哮喘的自主研发冷冻消融系统。在手术过程中，哮喘冷冻消融系统通过冷冻消融破坏肺部迷走神经，减少过度活化乙酰胆硷的释放，并减少黏液分泌，从而达到治疗哮喘的效果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","09997","BK1583","BK1222","09996","BK1100","06922","159883"],"gpt_icon":0},{"id":"2553176783","title":"大摩：未来医药在创新升级、制造升级及消费升级方面均有较大发展潜力 医药长期投资逻辑稳固","url":"https://stock-news.laohu8.com/highlight/detail?id=2553176783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553176783?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 21:06","pubTimestamp":1753362386,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，摩根士丹利基金研究管理部总监、大摩沪港深精选混合基金经理王大鹏在大摩沪港深精选混合2025年二季报中表达了对医药行业的继续看好，他认为，未来医药在创新升级、制造升级及消费升级方面均有较大的发展潜力，医药长期投资逻辑稳固。未来医药在创新升级、制造升级及消费升级方面均有较大的发展潜力，医药长期投资逻辑稳固。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ1G4Q59.USD","LU0267386448.USD","LU1732800096.USD","09939","LU2028103732.USD","BK4585","159938","LU1074936037.SGD","LU2271345857.HKD","LU0234570918.USD","LU1162221912.USD","LU0106261372.USD","LU0158827781.USD","LU0314104364.USD","LU0971096721.USD","LU1989772923.USD","LU2111349929.HKD","LU2133065610.SGD","LU1363072403.SGD","BK4516","BK1574","BK4581","LU1732799900.SGD","LU1989772840.SGD","LU2023251221.USD","LU0912757837.SGD","LU0225283273.USD","LU0158827948.USD","IE00BKVL7J92.USD","LU0106831901.USD","LU0006306889.USD","BK4588","BK4504","BK4127","LU1720051108.HKD","BK1161","BK1515","LU0795875169.SGD","LU2089284900.SGD","BK4534","LU0098860793.USD","LU1668664300.SGD","LU2089283258.USD","LU0320765646.SGD","LU1548497426.USD","LU2357305700.SGD","LU1720051017.SGD","LU2347655156.SGD","LU0795875086.SGD"],"gpt_icon":0},{"id":"2553200195","title":"中国抗体-B(03681)授出4658.6万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2553200195","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553200195?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 20:08","pubTimestamp":1753358897,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国抗体-B(03681)发布公告，于2025年7月24日，公司已根据2022年购股权计划向20名公司雇员及2名公司服务提供商授出4658.6万份购股权。购股权的行使价为每股2.630港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","03681","BK1161"],"gpt_icon":0},{"id":"2553207734","title":"KT International Investment Limited增持开拓药业-B(09939)50万股 每股作价2.598港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553207734","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553207734?lang=zh_cn&edition=fundamental","pubTime":"2025-07-24 19:54","pubTimestamp":1753358085,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月24日，KT International Investment Limited增持开拓药业-B(09939)50万股，每股作价2.598港元，总金额为129.9万港元。增持后最新持股数目约为4755.03万股，最新持股比例为10.63%。本次交易涉及其他关联方：Tong Youzhi。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1321633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","KT","LU0541501648.USD","BK1515","BK4115","09939","LU0541502299.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":32,"pageCount":4,"totalSize":638,"code":"91000000","status":"200"}]}}